CD274 and lung cancer: Therefore, these results suggests that PD-L1 rs4143815 and rs2282055 may be a biomarker for identifying patients for whom nivolumab may be particularly beneficial, which, as a result, may contribute to the clinical setting in the treatment of lung cancer.